Phase 3 trial results show remibrutinib significantly improves complete response rates in patients with 3 types of chronic inducible urticaria.

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

Novartis AG AG on Wednesday released positive topline results from its pivotal Phase 3 RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU). The Disease The primary endpoint was ...

Swiss pharma giant Novartis has announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU).

Novartis is on course to expand the label for its recently approved oral BTK inhibitor Rhapsido, after chalking up a win in chronic skin disorder chronic inducible urticaria (CINDU).

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was ...

The physical form of urticaria described in this question is cholinergic urticaria. This occurs in approximately 15% of people at some time during their lives. Cholinergic urticaria is a physical ...

BTS V once suffered from heat hives, also known as cholinergic urticaria. Learn its symptoms, causes, treatment, and how to prevent sweat-triggered hives. Do you know the fact that your favourite BTS ...